Jaguar Health Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
JAGX$0.44+7.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements Of Operations
| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| · Three Months Ended · · Six Months Ended | |||||||||||
| · June 30, · · June 30, | |||||||||||
| (In thousands, except share and per share data) · 2024 · 2023 · 2024 · 2023 | |||||||||||
| Product revenue, net | $2,721 | | $2,676 | | $5,072 | | $4,648 | ||||
| Operating expenses | | | | | | | | | | | |
| Cost of product revenue | | 427 | | | 491 | | | 857 | | | 836 |
| Research and development | 3,653 | | 4,277 | | 7,965 | | 9,052 | ||||
| Sales and marketing | | 1,524 | | | 1,573 | | | 2,967 | | | 3,457 |
| General and administrative | | 4,314 | | | 4,437 | | | 8,695 | | | 9,250 |
| Total operating expenses | 9,918 | | 10,778 | | 20,484 | | 22,595 | ||||
| Loss from operations | (7,197) | | (8,102) | | (15,412) | | (17,947) | ||||
| Interest income (expense) | 108 | | (3,453) | | (503) | | (5,634) | ||||
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | | (1,810) | | | (762) | | | (3,831) | | | (1,121) |
| Gain on extinguishment of debt | | — | | | — | | | 1,245 | | | — |
| Other income (expense) | | (729) | | | 26 | | | (495) | | | 14 |
| Loss before income tax expense | | (9,628) | | | (12,291) | | | (18,996) | | | (24,688) |
| Income tax expense | | — | | | — | | | — | | | — |
| Net loss | $(9,628) | | $(12,291) | | $(18,996) | | $(24,688) | ||||
| Net loss attributable to noncontrolling interest | $(136) | | $(141) | | $(278) | | $(336) | ||||
| Net loss attributable to common stockholders | $(9,492) | | $(12,150) | | $(18,718) | | $(24,352) | ||||
| Net loss per share, basic | $(4.04) | | $(41.35) | | $(15.93) | | $(128.12) | ||||
| Net loss per share, diluted | $(4.04) | | $(41.35) | | $(15.93) | | $(128.12) | ||||
| Weighted-average common stock outstanding, basic | 2,349,431 | | | 293,858 | | | 1,174,716 | | | 190,073 | |
| Weighted-average common stock outstanding, diluted | | 2,349,431 | | | 293,858 | | | 1,174,716 | | | 190,073 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.